Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial.

de Koning, Marie-Sophie L Y; van Dorp, Paulien; Assa, Solmaz; Pundziute-Do Prado, Gabija; Voskuil, Michiel; Anthonio, Rutger L; Veen, Duco; Leiner, Tim; Sibeijn-Kuiper, Anita J; van Goor, Harry; van Veldhuisen, Dirk J; van der Meer, Peter; Nijveldt, Robin; Lipsic, Erik; van der Harst, Pim

Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial.

de Koning, Marie-Sophie L Y; van Dorp, Paulien; Assa, Solmaz; Pundziute-Do Prado, Gabija; Voskuil, Michiel; Anthonio, Rutger L; Veen, Duco; Leiner, Tim; Sibeijn-Kuiper, Anita J; van Goor, Harry; van Veldhuisen, Dirk J; van der Meer, Peter; Nijveldt, Robin; Lipsic, Erik; van der Harst, Pim.

Afiliación

de Koning MLY; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
van Dorp P; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Assa S; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Pundziute-Do Prado G; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Voskuil M; Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, the Netherlands.
Anthonio RL; Department of Cardiology, Treant Hospital, location Scheper, Emmen, the Netherlands.
Veen D; Department of Methodology and Statistics, Utrecht University, Utrecht, the Netherlands.
Leiner T; Optentia Research Programme, North-West University, Vanderbijlpark Campus, Vanderbijlpark, South Africa.
Sibeijn-Kuiper AJ; Department of Radiology, University Medical Centre Utrecht, Utrecht, the Netherlands.
van Goor H; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
van Veldhuisen DJ; University of Groningen, University Medical Centre Groningen, Cognitive Neuroscience Centre, Groningen, the Netherlands.
van der Meer P; Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Nijveldt R; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Lipsic E; Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
van der Harst P; Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands.

JACC Basic Transl Sci ; 8(10): 1285-1294, 2023 Oct.

Article en En | MEDLINE | ID: mdl-38094689

ABSTRACT

ABSTRACT

In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.

Palabras clave

clinical trial; hydrogen sulfide; ischemia-reperfusion injury; myocardial infarction; randomized controlled trial; thiosulfates

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google